US Patent

US8088786 — Layered pharmaceutical formulations

Formulation · Assigned to Orexigen Therapeutics Inc · Expires 2029-02-03 · 3y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects layered pharmaceutical formulations with an intermediate layer that dissolves in the body, leaving intact two or more pharmaceutical layers.

USPTO Abstract

In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.

Drugs covered by this patent

Patent Metadata

Patent number
US8088786
Jurisdiction
US
Classification
Formulation
Expires
2029-02-03
Drug substance claim
No
Drug product claim
Yes
Assignee
Orexigen Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.